Treating head and neck cancer in the age of immunotherapy: a 2023 update

A Bhatia, B Burtness - Drugs, 2023 - Springer
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. While this approach …

Review of osteoradionecrosis of the jaw: radiotherapy modality, technique, and dose as risk factors

E Topkan, A Kucuk, E Somay, B Yilmaz… - Journal of Clinical …, 2023 - mdpi.com
Radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) is the cornerstone of organ-
sparing or adjuvant therapy for nearly all head and neck cancers. Unfortunately, aggressive …

Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC

R Saddawi-Konefka, A O'Farrell, F Faraji… - Nature …, 2022 - nature.com
Despite the promise of immune checkpoint inhibition (ICI), therapeutic responses remain
limited. This raises the possibility that standard of care treatments delivered in concert may …

Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

C Petit, B Lacas, JP Pignon, QT Le, V Grégoire… - The Lancet …, 2021 - thelancet.com
Background Randomised, controlled trials and meta-analyses have shown the survival
benefit of concomitant chemoradiotherapy or hyperfractionated radiotherapy in the treatment …

The key differences between human papillomavirus-positive and-negative head and neck cancers: biological and clinical implications

SF Powell, L Vu, WC Spanos, D Pyeon - Cancers, 2021 - mdpi.com
Simple Summary Head and neck cancer (HNC) is the sixth most common cancer, causing
almost half a million deaths worldwide every year. The two subtypes of HNC are distinctly …

[HTML][HTML] Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): an update on 26 trials and 7080 patients

P Blanchard, AWM Lee, A Carmel, NW Tong… - Clinical and translational …, 2022 - Elsevier
Purpose Chemotherapy, when added to radiotherapy, improves survival in locally advanced
nasopharyngeal carcinoma (NPC). This article presents the second update of the Meta …

De-escalation strategies of (chemo) radiation for head-and-neck squamous cell cancers—HPV and beyond

A Rühle, AL Grosu, NH Nicolay - Cancers, 2021 - mdpi.com
Simple Summary HPV-related oropharyngeal squamous cell carcinoma patients have a very
good prognosis but are often suffering from long-term treatment-induced toxicities …

Radiotherapy and systemic therapies: focus on head and neck Cancer

F De Felice, CG Cattaneo, P Franco - Cancers, 2023 - mdpi.com
Simple Summary This review provides some highlights in the current radio (chemo) therapy
strategy for head and neck squamous cell carcinoma (HNSCC). The aim is to lead to a better …

Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts

L Koi, V Bitto, C Weise, L Möbius, A Linge… - Journal of Translational …, 2023 - Springer
Background Tumor hypoxia is associated with resistance to radiotherapy and
chemotherapy. In head and neck squamous cell carcinoma (HNSCC), nimorazole, an …

[HTML][HTML] Larynx cancer survival model developed through open-source federated learning

CR Hansen, G Price, M Field, N Sarup… - Radiotherapy and …, 2022 - Elsevier
Introduction Federated learning has the potential to perform decentralised analysis;
however, there are some obstacles to survival analyses as there is a risk of data leakage …